homehealthcare NewsShilpa Medicare secures final US FDA nod for psoriatic arthritis drug

Shilpa Medicare secures final US FDA nod for psoriatic arthritis drug

Shilpa Medicare revealed that Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.

By Tanmay Tiwary  Apr 11, 2023 12:20:01 PM IST (Updated)

2 Min Read
Shares of Shilpa Medicare gained over 10 percent on Tuesday,  after the pharmaceutical company said on Monday that it received the United States Food and Drug Administration's (USFDA) final approval for its Abbreviated New Drug Application (ANDA), Apremilast Tablets, 10 mg, 20 mg, and 30 mg. Apremilast Tablets are used for the treatment of adult patients with active psoriatic arthritis.

The product is executed from a contract manufacturing site, the company said in a statement.

Shilpa Medicare revealed that Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.